The U.S. Food and Drug Administration has made changes to the labels for fluoroquinolone antibacterial drugs administered by mouth or injection to address potential serious safety issues. The revised “boxed warning,” the agency’s strongest warning, notes that the drugs are “associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system” that can occur together. “Health care professionals should not prescribe systemic fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis (ABECB), and uncomplicated urinary tract infections (UTI) because the risks outweigh the benefits in these patients,” the agency states. For more, see the FDA Safety Announcement.

Related News Articles

Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…
Headline
President Trump July 7 issued an executive order, “Extending the Modification of the Reciprocal Tariff Rates,” which extends the original July 9 reciprocal…
Headline
The Centers for Disease Control and Prevention July 7 announced it is streamlining H5N1 bird flu updates with its routine influenza data given the low public…
Headline
A study published July 7 by JAMA found children’s health has significantly worsened from 2007 to 2023. Researchers studied changes in child mortality; chronic…
Headline
The AHA encourages hospitals and health systems that are committed to leadership and innovation in improving quality and advancing health to apply for its 2026…
Headline
The National Institutes of Health July 3 announced that all NIH-funded research published in scientific journals must be made publicly accessible immediately…